Chimeric Therapeutics is trading at A$0.01, with a -8.33% change, broadly consistent with biotechnology-sector weakness; XBI is down 4.24% during the regular session.
- No verified company-specific announcement was identified for September 2, 2026.
- On August 19, the company reported halted enrollment in the CHM-2101 trial after dose-limiting toxicities.
- Subsequent coverage described a planned pivot to an in vivo approach.